A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia.

Int J Neuropsychopharmacol · 2016 · PMC5006195 · PMID 26979830

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

When the percentage of time in each sleep stage (rather than minutes in each stage) was analyzed, only the percentage of REM sleep showed nominally significant increases compared with placebo for most of the filorexant doses (night 1: 2.5% to 3.3%; week 4: -0.8% to 2.1%).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.